{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"12.9","value":"9.2"},{"comment":"Upper CI not calculable due to insufficient number of events.","groupId":"OG001","lowerLimit":"2.1","upperLimit":"NA","value":"4.1"},{"comment":"Upper and lower CI not calculable due to insufficient number of events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"10.0"},{"comment":"Median and CI not calculable due to insufficient number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper CI not calculable due to insufficient number of events.","groupId":"OG004","lowerLimit":"1.7","upperLimit":"NA","value":"11.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"The PFS time was defined as the time from the date of consent signed to the date of documented disease progression or death due to any cause, whichever occurred first. Participants without progression or death were censored at the date of the last disease assessment. Participants who received subsequent anticancer therapy were censored at the date of the last disease assessment before subsequent anticancer therapy. The Kaplan-Meier product-limit method was used to estimate the 1-year PFS rate, as well as the corresponding 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG000","title":"KRAS/NRAS WT"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG001","title":"KRAS/NRAS Mut"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG002","title":"KRAS/NRAS Missing"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG003","title":"CXCR4/2 High"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG004","title":"CXCR4/2 Low"}],"paramType":"MEDIAN","populationDescription":"PP Analysis Set: Included participants who received at least 1 dose of tipifarnib and had a baseline disease assessment and at least 1 post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}